๐ŸŒ EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

๐Ÿงช

Trial Match

Clinical trials test new treatments โ€” sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

๐ŸŽฏ Match trials to me

27 recruiting trials

for Non-clear Renal Cell Carcinoma

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors NCT06026410Phase 138 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Los Angeles Kura Oncology, Inc. ยท Tests: Darlifarnib, Cabozantinib, Adagrasib GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors NCT04977453Phase 1, Phase 213 sites๐Ÿ“ New York๐Ÿ“ New York๐Ÿ“ Huntersville GI Innovation, Inc. ยท Tests: GI-101, Pembrolizumab (KEYTRUDAยฎ), Lenvatinib, GI-101A 18F-T2 PET/CT Imaging for CAIX Positive Solid Tumors NCT07557225NA1 site๐Ÿ“ Beijing Peking University First Hospital ยท Tests: 18F-T2 PET/CT Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors NCT04777994Phase 130 sites๐Ÿ“ Tucson๐Ÿ“ New Haven๐Ÿ“ Baltimore Calico Life Sciences LLC ยท Tests: ABBV-CLS-484, Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI), Programmed Cell Deatโ€ฆ CAIX-targeted PET/CT in Solid Tumors NCT07833085NA1 site๐Ÿ“ Wuhan Zhongnan Hospital ยท Tests: 68Ga-CAIX Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors NCT05856981Phase 17 sites๐Ÿ“ Detroit๐Ÿ“ St Louis๐Ÿ“ Canton Sairopa B.V. ยท Tests: ADU-1805, Pembrolizumab 89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study NCT06750419Phase 38 sites๐Ÿ“ Beijing๐Ÿ“ Hangzhou๐Ÿ“ Hubei Telix Pharmaceuticals (Innovations) Pty Limited ยท Tests: 89Zr-TLX250 PET/CT Postoperative Adjuvant Therapy for Non-clear Renal Cell Carcinoma With High-risk Recurrence Factors NCT05768464Phase 22 sites๐Ÿ“ Nanjing๐Ÿ“ Nanning The Affiliated Nanjing Drum Tower Hospital of Nanjing Univeโ€ฆ ยท Tests: Toripalimab, Axitinib A Study of MGC026 in Participants With Advanced Solid Tumors NCT06242470Phase 112 sites๐Ÿ“ Los Angeles๐Ÿ“ Grand Rapids๐Ÿ“ Lake Success MacroGenics ยท Tests: MGC026 Dose Escalation, MGC026 Dose for Expansion A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma NCT07688187Phase 11 site๐Ÿ“ Omaha PeptiDream Inc. ยท Tests: PD-32766D (a Copper-64 [64Cu] labeled peptide), PD-32766T (an Actinium-225 [225Ac] labeled peptide) Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma NCT07300241Phase 114 sites๐Ÿ“ Duarte๐Ÿ“ San Diego๐Ÿ“ New Haven Neomorph, Inc ยท Tests: NEO-811 A First-In Human (FIH) Study to Find Out How Well REGN10597 Medicine Given Alone or in Combination With Cemiplimab Works in Adult Participants Who Have Cancer With Tumors That Have Spread in Their Body NCT06413680Phase 1, Phase 211 sites๐Ÿ“ Los Angeles๐Ÿ“ San Francisco๐Ÿ“ North Haven Regeneron Pharmaceuticals ยท Tests: REGN10597, Cemiplimab Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rฮฑ Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer NCT05267626Phase 1, Phase 217 sites๐Ÿ“ Miami๐Ÿ“ Grand Rapids๐Ÿ“ Minneapolis Aulos Bioscience, Inc. ยท Tests: AU-007, Aldesleukin, Avelumab, Nivolumab CD70-targeted immunoPET Imaging of Malignant Cancers NCT06852638Phase 21 site๐Ÿ“ Shanghai RenJi Hospital ยท Tests: [18F]F-RESCA-RCCB6, [18F]F-RESCA-R8B4, [68Ga]Ga-NOTA-R8B4, [18F]F-RESCA-RD06, [68Ga]Ga-NOTA-RD06 A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies NCT07195916Phase 122 sites๐Ÿ“ Duarte๐Ÿ“ La Jolla๐Ÿ“ Ann Arbor Incyte Corporation ยท Tests: INCA036873 A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors NCT05706129Phase 1, Phase 210 sites๐Ÿ“ Melbourne๐Ÿ“ Sydney๐Ÿ“ Clermont-Ferrand Lumara Bio Oncologics GmbH ยท Tests: [68Ga]Ga-DPI-4452, [177Lu]Lu-DPI-4452 Neoadjuvant Zanzalintinib Plus Nivolumab in Patients With Locally Advanced and/or Inoperable Clear Cell Renal Cell Carcinoma With or Without Non-measurable Metastasis NCT06794229Phase 24 sites๐Ÿ“ St Louis๐Ÿ“ Philadelphia๐Ÿ“ Dallas Qian Qin ยท Tests: Zanzalintinib, Nivolumab A Phase I/II Trial of UCB4594 in Participants With Advanced Cancer NCT06380816Phase 1, Phase 24 sites๐Ÿ“ London๐Ÿ“ Manchester๐Ÿ“ Newcastle upon Tyne Cancer Research UK ยท Tests: UCB4594 Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors NCT05176483Phase 1122 sites๐Ÿ“ Phoenix๐Ÿ“ Tucson๐Ÿ“ Palo Alto Exelixis ยท Tests: Zanzalintinib, Nivolumab, Ipilimumab, Nivolumab + Relatlimab, Prednisone Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma NCT06302569Phase 21 site๐Ÿ“ Milan Giuseppe Procopio ยท Tests: Pembrolizumab + Enfortumab Vedotin Phase 2 Study of Combination Tivozanib and Nivolumab in Advanced Non-Clear Cell Renal Cell Carcinoma NCT06053658Phase 26 sites๐Ÿ“ Irvine๐Ÿ“ Boston๐Ÿ“ Boston M.D. Anderson Cancer Center ยท Tests: Tivozanib, Nivolumab Ivonescimab in the Treatment of Multiple Advanced Tumors NCT06683846Phase 21 site๐Ÿ“ Shanghai Fudan University ยท Tests: Ivocizumab A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors NCT06270706Phase 122 sites๐Ÿ“ New Haven๐Ÿ“ Atlanta๐Ÿ“ Grand Rapids Pliant Therapeutics, Inc. ยท Tests: PLN-101095, PLN-101095, PLN-101095, PLN-101095, PLN-101095 Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors NCT07517198Phase 13 sites๐Ÿ“ Los Angeles๐Ÿ“ Fort Worth๐Ÿ“ West Valley City Exscientia AI Ltd., a wholly owned subsidiary of Recursion โ€ฆ ยท Tests: EXS74539 Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform NCT06349642n/a3 sites๐Ÿ“ Phoenix๐Ÿ“ Jacksonville๐Ÿ“ Rochester Mayo Clinic ยท Tests: Biospecimen Collection, Tissue Collection A Beta-only IL-2 ImmunoTherapY Study NCT05086692Phase 1, Phase 228 sites๐Ÿ“ San Diego๐Ÿ“ San Francisco๐Ÿ“ Santa Monica Medicenna Therapeutics, Inc. ยท Tests: MDNA11, Pembrolizumab (KEYTRUDAยฎ) Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors NCT06750185Phase 1, Phase 211 sites๐Ÿ“ Louisville๐Ÿ“ Grand Rapids๐Ÿ“ Huntersville BioNTech SE ยท Tests: BNT317 DL1, BNT317 DL2, BNT317 DL3, BNT317 DL4, BNT317 DL5
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy